Skip to content
An official website of the OECD. Find out more
Created by the Public Governance Directorate

This website was created by the OECD Observatory of Public Sector Innovation (OPSI), part of the OECD Public Governance Directorate (GOV).

How to validate authenticity

Validation that this is an official OECD website can be found on the Innovative Government page of the corporate OECD website.

Extremely Vulnerable Persons Service

Innovative response

A dedicated support service for people with a medical condition which makes them extremely vulnerable to coronavirus (COVID-19).

Extermely vulnerable includes people who have had a solid organ transplant; have any cancer and are getting chemotherapy; have lung cancer and are getting radical radiotherapy; have cancer of the blood or bone marrow, at any stage of treatment - for example, leukaemia, lymphoma or myeloma; have any cancer for which you’re getting immunotherapy or other continuing antibody treatments; have any cancer for which you’re getting a targeted treatment which can affect the immune system - for example, protein kinase inhibitors or PARP inhibitors; have had bone marrow or stem cell transplants in the last 6 months, or are still taking immunosuppression drugs; have a severe respiratory condition - including cystic fibrosis, severe asthma or severe COPD (Chronic Obstructive Pulmonary Disease); have a rare disease or inborn error of metabolism that significantly increases your risk of infection - for example SCID or homozygous sickle cell; are getting an immunosuppression therapy that’s sufficient to significantly increase your risk of infection if are pregnant, and have a significant congenital or acquired heart disease.

Specific issues addressed and anticipated impact

Support for vulnerable people

Organisations/institutions involved

Government Digital Service

Level(s) of government:
  • National/Federal government

Issues being addressed:

  • Patient care
  • Social effects of the crisis

Response tags:

Date Submitted:

8 April 2020